China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2019
October 2019
1
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements, misleading statements, or important omissions carried in this report,
and shall take all responsibilities, individual and/or joint, for the reality,
accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.
Lin Zhaoxiong, person in charge of the Company, head of the accounting works
Wei Pingxiao and Wang Ying, accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic, accurate and complete.
2
Section II. Basic information of Company
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□ Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets (RMB) 34,816,993,187.67 28,930,300,519.97 20.35%
Net assets attributable to
shareholders of listed company 12,451,750,624.00 11,618,432,603.28 7.17%
(RMB)
Increase/decrease in
Increase/decrease in
Year-begin to end of comparison with
Current period comparison with same
the Period year-begin to
period of last year
period-end of last year
Operating revenue (RMB) 13,647,793,431.64 24.21% 38,875,940,809.07 22.38%
Net profit attributable to
shareholders of the listed company 311,310,706.52 9.14% 962,144,066.92 3.79%
(RMB)
Net profit attributable to
shareholders of the listed company
303,365,280.52 7.45% 943,065,728.47 4.14%
after deducting non-recurring gains
and losses (RMB)
Net cash flow arising from
-- -- 1,072,962,161.22 90.24%
operating activities (RMB)
Basic earnings per share
0.735 10.36% 2.247 3.79%
(RMB/Share)
Diluted earnings per share
0.735 10.36% 2.247 3.79%
(RMB/Share)
0.09 percentage points 1.27 percentage points
Weighted average ROE 2.53% 7.94%
decline decline
Note: the weighted average ROE has 0.09 percentage points down from same period last year, and 1.27 percentage points down at
year-begin to period-end over same period last year, mainly because a strategy investor was introduced by Guoda Drugstore in
second half of last year.
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
3
Amount from year-begin to
Item Note
end of the Period
Gains/losses from the disposal of non-current asset (including the
487,779.48
write-off that accrued for impairment of assets)
Governmental subsidy reckoned into current gains/losses (not
Received vary taxes subsidies
including the subsidy enjoyed in quota or ration according to
29,325,892.83 and financial rewards in the
national standards, which are closely relevant to enterprise’s
period
business)
Net gain/loss of impairment
Reversal of impairment reserve for account receivable with
1,216,744.26 provision switch-back for
separate impairment testing
receivables
The gains obtained from offering
Gains/losses on entrusted loans 2,563,975.31 entrust loans to China National
Zhijun (Suzhou)
Other non-operating income and expenditure except for the
2,455,770.91
aforementioned items
Other gains/losses satisfy a definition of extraordinary
22,424.73
gains/losses
Less: impact on income tax 8,393,659.91
Impact on minority shareholders’ equity (post-tax) 8,600,589.16
Total 19,078,338.45 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total preference shareholders
Total common shareholders at the with voting rights recovered at
21,620 0
end of report period end of reporting period (if
applicable)
4
Top ten shareholders
Amount of Number of share pledged/frozen
Nature of Proportion of Amount of shares
Shareholders restricted shares
shareholder shares held held State of share Amount
held
Sinopharm Group State-owned
56.06% 239,999,991 55,057,700
Co., Ltd. corporate
Hong Kong
Securities Overseas
4.48% 19,163,870
Clearing corporate
Company Ltd
HTHK/CMG
FSGUFP-CMG
Overseas
FIRST STATE 2.68% 11,469,644
corporate
CHINA
GROWTH FD
China National
Pharmaceutical State-owned
1.24% 5,323,043 5,323,043
Foreign Trade corporate
Corp.
Fidelity
Investment
Management Overseas
1.13% 4,825,907
(Hong Kong) corporate
Limited - Client’s
fund
# Beijing
Haoqing Fortune
Investment Domestic non
Management Co., state-owned 0.96% 4,118,716
Ltd. – Haoqing corporate
Value Stable No.8
Investment Fund
Basic endowment Domestic non
insurance fund- state-owned 0.95% 4,080,913
portfolio 1003 corporate
Central Huijin State-owned
0.89% 3,804,400
Investment Ltd. corporate
Bank of China - Domestic non
Harvest Health state-owned 0.76% 3,258,525
Care Stock corporate
Securities
5
Investment Funds
BBH BOS S/A
FIDELITY FD - Overseas
0.76% 3,246,061
CHINA FOCUS corporate
FD
Particular about top ten shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 184,942,291 184,942,291
shares
Hong Kong Securities Clearing RMB ordinary
19,163,870 19,163,870
Company Ltd shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
11,469,644 listed foreign 11,469,644
STATE CHINA GROWTH FD
shares
China National Pharmaceutical RMB ordinary
5,323,043 5,323,043
Foreign Trade Corp. shares
Fidelity Investment Management RMB ordinary
4,825,907 4,825,907
(Hong Kong) Limited - Client’s fund shares
# Beijing Haoqing Fortune
Investment Management Co., Ltd. – RMB ordinary
4,118,716 4,118,716
Haoqing Value Stable No.8 shares
Investment Fund
Basic endowment insurance fund- RMB ordinary
4,080,913 4,080,913
portfolio 1003 shares
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
Bank of China - Harvest Health Care RMB ordinary
3,258,525 3,258,525
Stock Securities Investment Funds shares
Domestically
BBH BOS S/A FIDELITY FD -
3,246,061 listed foreign 3,246,061
CHINA FOCUS FD
shares
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the other tradable shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Explanation on top ten common Beijing Hao Qing Wealth Investment Management Co., Ltd. –Hao Qing Value Stable No.8
shareholders involving margin Investment Fund holds 4,048,216 shares of the Company through margin trading and
business (if applicable) refinancing secured security account
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
6
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
7
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Note receivable: decreased 772 million Yuan over that of period-begin with growth rate of -56.88%, mainly because according to
the presentation requirements of statement, at end of the period, the bank acceptance bill in note receivable was listed under the item
of “Receivable financing”;
2. Accounts receivable: increased 3844 million Yuan over that of period-begin with growth rate of 41.17%, mainly because volume
of business increased in the period, account receivable goes up and payment collection period increased at the same time;
3. Receivable financing: increased 400 million Yuan over that of period-begin, mainly because according to the presentation
requirements of statement, at end of the period, the bank acceptance bill in note receivable was listed under the item of “Receivable
financing”;
4. Interest receivable: increased 6.1777 million Yuan over that of period-begin with growth rate of 75.12%, mainly because the
deposit interest increased;
5. Right-of-use assets: increased 1860 million Yuan over that of period-begin, mainly due to the implementation of new leasing
standards in the period;
6. Total non-current assets: increased 2114 million Yuan over that of period-begin with growth rate of 47.66%, mainly because the
right-of-use assets increased for new leasing standards implemented in the period;
7. Accounts payable: increased 2678 million Yuan over that of period-begin with growth rate of 41.41%, mainly because volume of
business increased in the period, purchase volume and account payable increase accordingly;
8. Dividends payable: increased 4.7064 million Yuan over that of period-begin with growth rate of 73.66%, mainly because the
accrual of bonus of minority shareholders payable increased;
9. Non-current liabilities due within one year: increased 533 million Yuan over that of period-begin with growth rate of 9,093.11%,
mainly due to the implementation of new leasing standards in the period, the ending book value of leasing liabilities due for
repayment within one year from the balance sheet date, was listed under the item of “Non-current liabilities due within one year”;
10. Other current liabilities: increased 330,700 Yuan over that of period-begin with growth rate of 113.07%, mainly because the
output tax amount ready for transfer increased over that of period-begin;
11. Long-term borrowings: decreased 31.60 million Yuan over that of period-begin with growth rate of -100.00%, mainly because
the long-term loan was re-classified to non-current liability due within one year;
8
12. Lease liabilities: increased 1165 million Yuan over that of period-begin, mainly due to the implementation of new leasing
standards in the period;
13. Long-term payables: decreased 3.764 million Yuan over that of period-begin with growth rate of -82.47%, mainly due to the
implementation of new leasing standards in the period, the finance lease before the first execution date was adjusted to lease
liabilities;
14. Total non-current liabilities: increased 1126 million Yuan over that of period-begin with growth rate of 422.45%, mainly because
lease liabilities increased for the implementation of new leasing standards in the period;
15. Total liabilities: increased 4875 million Yuan over that of period-begin with growth rate of 32.44%, mainly because volume of
business increased in the period, purchase volume and account payable increase accordingly;
16. Operating revenue: increased 7109 million Yuan on a y-o-y basis with growth rate of 22.38%, mainly because business income
increased for the good business performance in the period;
17. Operating costs: increased 6552 million Yuan on a y-o-y basis with growth rate of 23.30%, mainly because business income
increased for the good business performance in the period, business cost increased correspondingly;
18. Finance costs: increased 69.5683 million Yuan on a y-o-y basis with growth rate of 88.87%, mainly due to the implementation of
new leasing standards in the period, during the lease terms, interest expenses shall be calculated according to the discount rate for
lease liabilities, there was no such item in the same period last year;
19. Other incomes: increased 14.7031 million Yuan on a y-o-y basis with growth rate of 118.53%, mainly because fiscal subsidy
received in period increased;
20. Impairment losses on financial assets: increased 15.1252 million Yuan on a y-o-y basis with growth rate of 3156.28%, mainly
because the account receivable has increased over same period last year at end of the period, than the bad debt provision accrual in
the period increased on a y-o-y basis;
21. Impairment losses: increased 714,900 Yuan on a y-o-y basis with growth rate of 613.43%, mainly because reversal of the
inventory falling price reserves declined from a year earlier;
22. Gain on disposal of assets: decreased 3.7735 million Yuan on a y-o-y basis with growth rate of -86.59%, mainly because at same
period last year, there was a property funds collected by the government was received by the Company while no such item in the
period;
23. Minority shareholders’ gains and losses: increased 81.7569 million Yuan on a y-o-y basis with growth rate of 97.93%, mainly
because at second half of 2018, subsidiary Guoda Drugstore introduced a strategy investor, the gains/losses of minority shareholders
increased on a y-o-y basis in the period;
24. Total comprehensive income attributable to minority shareholders: increased 81.7569 million Yuan on a y-o-y basis with growth
rate of 97.93%, mainly because at second half of 2018, subsidiary Guoda Drugstore introduced a strategy investor, the total
comprehensive income attributable to minority shareholders increased correspondingly;
9
25. Tax refunds: increased 1.7933 million Yuan on a y-o-y basis with growth rate of 104.58%, mainly because the tax refund
increased compared with same period of last year;
26. Cash payments related to other operating activities: decreased 484 million Yuan on a y-o-y basis with growth rate of -38.77%,
mainly due to the implementation of new leasing standards in the period, the rents paid in the period are reckoned into cash paid with
other financing activity concerned, while no such item at same period lat year;
27. Net cash flows from operating activities: increased 509 million Yuan on a y-o-y basis with growth rate of 90.24%, mainly due to
the good operation performance, cash received for goods sales and providing services increased correspondingly; and due to the
implementation of new leasing standards in the period, the rents paid in the period are reckoned into cash paid with other financing
activity concerned, while no such item at same period lat year;
28. Cash received from returns on investments: decreased 52.7204 million Yuan on a y-o-y basis with growth rate of -40.26%,
mainly because the investment dividend received from joint venture declined on a y-o-y basis;
29. Cash received with other investing activities: decreased 96.7471 million Yuan on a y-o-y basis with growth rate of -95.54%,
mainly because at same period last year, received a consideration for reorganization of Shyndec Pharmaceutical, while no such item
in the period;
30. Subtotal of cash in-flow from investing activities: decreased 150 million Yuan on a y-o-y basis with growth rate of -63.14%,
mainly because the investment dividend received from joint venture declined on a y-o-y basis; and at same period last year, received
a consideration for reorganization of Shyndec Pharmaceutical, while no such item in the period;
31. Net cash paid from disposal of subsidiaries and other business units: increased 5.328 million Yuan on a y-o-y basis, mainly due to
the investment amount for new company acquisition in the period, while no such item at same period last year;
32. Cash payments related to other investing activities: decreased 78.3182 million Yuan on a y-o-y basis with growth rate of -97.99%,
mainly because at same period last year, the entrusted loans of Sinopharm Zhijun (Suzhou) was paid while no such item in the
period;
33. Net cash flows from investing activities: decreased 84.2184 million Yuan on a y-o-y basis with growth rate of -102.33%, mainly
because the investment dividend received from joint venture declined on a y-o-y basis; and at same period last year, received a
consideration for reorganization of Shyndec Pharmaceutical, while no such item in the period;
34. Cash proceeds from investments by others: decreased 2744 million Yuan on a y-o-y basis with growth rate of -98.40%, mainly
because at same period last year, subsidiary Guoda Drugstore received a capital increased amount from strategy investor, while no
such item in the period;
35. Cash received from borrowings: decreased 32.9702 million Yuan on a y-o-y basis with growth rate of -66.38%, mainly because
the bank current loans in the period declined on a y-o-y basis;
36. Cash receipts related to other financing activities: decreased 107 million Yuan on a y-o-y basis with growth rate of -98.19%,
mainly because at same period last year, received a money order security while no such item in the period;
10
37. Sub-total of cash inflows from financing activities: decreased 2884 million Yuan on a y-o-y basis with growth rate of -97.86%,
mainly because at same period last year, subsidiary Guoda Drugstore received a capital increased amount from strategy investor,
while no such item in the period;
38. Cash payments for distribution of dividends or profit and interest expenses: increased 174 million Yuan on a y-o-y basis with
growth rate of 62.86%, mainly because the interest of supply chain financing increased on a y-o-y basis in the period;
39. Cash payments related to other financing activities: increased 544 million Yuan on a y-o-y basis with growth rate of 896.87%,
mainly due to the implementation of new leasing standards in the period, the rents paid in the period are reckoned into cash paid with
other financing activity concerned, while no such item at same period lat year;
40. Sub-total of cash outflows from financing activities: increased 712 million Yuan on a y-o-y basis with growth rate of 170.65%,
mainly due to the implementation of new leasing standards in the period, the rents paid in the period are reckoned into cash paid with
other financing activity concerned and the interest of supply chain financing increased on a y-o-y basis in the period;
41. Net cash flows from financing activities: decreased 3596 million Yuan on a y-o-y basis with growth rate of -142.10%, mainly
because at same period last year, subsidiary Guoda Drugstore received a capital increased amount from strategy investor, while no
such item in the period;
42. Eefect of foreign exchange rate changes on cash and cash equivalents: increased 138,500 Yuan on a y-o-y basis with growth rate
of 44.04%, mainly due to the impact of exchange rate changes;
43. Net increase incash and cash equivalents: decreased 3171 million Yuan on a y-o-y basis with growth rate of -105.28%, mainly
because at same period last year, subsidiary Guoda Drugstore received a capital increased amount from strategy investor, while no
such item in the period;
44. Cash and cash equivalents at beginning of the year: increased 3959 million Yuan on a y-o-y basis with growth rate of 107.76%,
mainly because at second half of last year, subsidiary Guoda Drugstore received a capital increased amount from strategy investor,
while no such item at period-begin of last year.
II. Progress and influence of the main events as well as solution analysis specification
□ Applicable √ Not applicable
Progress of shares buy-back
□Applicable √Not applicable
Implementation progress of the reduction of repurchases shares by centralized bidding
□Applicable √Not applicable
11
III. Commitments that the company, shareholders, actual controller, offeror, directors,
supervisors, senior management or other related parties have fulfilled during the reporting
period and have not yet fulfilled by the end of reporting period
□ Applicable √ Not applicable
There are no commitments that the company, shareholders, actual controller, offeror, directors, supervisors, senior management or
other related parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.
IV. Particular about security investment
□ Applicable √ Not applicable
The Company had no security investment in Period.
V. Trust financing
□ Applicable √ Not applicable
The Company had no trust financing in Period.
VI. Particulars about derivatives investment
□ Applicable √ Not applicable
The Company had no derivatives investment in Period.
VII. Registration form of receiving research, communication and interview in the report
period
□Applicable √ Not applicable
The Company has no research, communication and interview accepted in the Period.
VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.
IX. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.
12
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2019-09-30
In RMB
Item 2019-9-30 2018-12-31
Current assets:
Monetary funds 7,810,810,868.51 8,089,781,304.56
Settlement provisions
Capital lent
Tradable financial assets
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Note receivable 585,211,751.81 1,357,311,929.63
Account receivable 13,181,036,029.36 9,336,861,647.92
Receivable financing 400,387,183.26
Advances to suppliers 424,448,767.10 583,484,515.95
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 522,497,740.14 643,493,359.32
Including: Interest receivable 14,401,063.47 8,223,327.64
Dividend receivable
Buying back the sale of financial
assets
Inventories 5,274,930,261.55 4,389,335,942.19
Contractual assets
Assets held for sale
13
Non-current asset due within one
year
Other current assets 69,262,261.99 95,347,629.18
Total current assets 28,268,584,863.72 24,495,616,328.75
Non-current assets:
Loans and payments on behalf
Debt investment
Finance asset available for sales
Other debt investment
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 2,107,690,039.44 1,880,393,786.10
Other equity instruments
13,685,760.00 13,685,760.00
investment
Other non-current financial assets 140,000,000.00 140,000,000.00
Investment properties 139,672,194.89 144,894,495.97
Fixed assets 583,995,191.53 607,933,827.67
Construction in progress 35,681,041.39 36,412,614.61
Productive biological asset
Oil and gas asset
Right-of-use assets 1,860,064,348.67
Intangible assets 314,251,903.10 319,207,126.15
Expense on Research and
Development
Goodwill 871,041,800.60 833,547,800.60
Long-term prepaid expenses 330,156,094.79 311,328,706.46
Deferred tax assets 78,340,768.87 74,914,209.95
Other non-current asset 73,829,180.67 72,365,863.71
Total non-current asset 6,548,408,323.95 4,434,684,191.22
Total assets 34,816,993,187.67 28,930,300,519.97
Current liabilities:
Short-term borrowings 2,417,214,478.23 2,597,652,702.43
Loan from central bank
Capital borrowed
Transactional financial liability
14
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Note payable 4,087,524,569.31 3,416,755,681.80
Account payable 9,146,870,315.29 6,468,535,961.17
Accounts received in advance
Contractual liability 226,493,600.53 255,590,612.37
Selling financial asset of
repurchase
Absorbing deposit and interbank
deposit
Security trading of agency
Security sales of agency
Employee benefits payable 208,422,163.84 231,866,407.40
Taxes payable 240,761,116.26 241,980,412.72
Other account payable 1,639,777,109.48 1,539,436,971.93
Incl: Interest payable 23,295,353.88 21,906,660.63
Dividend payable 11,095,744.80 6,389,320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within
538,837,869.81 5,861,324.37
one year
Other current liabilities 623,159.83 292,465.75
Total current liabilities 18,506,524,382.58 14,757,972,539.94
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31,600,000.00
Bonds payable
Including: Preferred stock
Perpetual capital
securities
Lease liability 1,165,308,548.15
Long-term payable 800,000.00 4,563,978.52
15
Long-term employee benefits
1,915,000.00 2,050,000.00
payable
Accrual liability
Deferred income 90,111,450.25 91,491,170.40
Deferred tax liabilities 66,067,559.30 67,605,161.88
Other non-current liabilities 68,388,290.57 69,241,176.18
Total non-current liabilities 1,392,590,848.27 266,551,486.98
Total liabilities 19,899,115,230.85 15,024,524,026.92
Owner’s equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: Preferred stock
Perpetual capital
securities
Capital surplus 4,363,409,728.51 4,320,984,981.51
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214,063,491.50 214,063,491.50
Provision of general risk
Retained earnings 7,446,150,420.99 6,655,257,147.27
Shareholders’ equity attributable to
12,451,750,624.00 11,618,432,603.28
shareholders of the parent
Non-controlling interests 2,466,127,332.82 2,287,343,889.77
Total shareholders’ equity 14,917,877,956.82 13,905,776,493.05
Total liabilities and shareholders’ equity 34,816,993,187.67 28,930,300,519.97
Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item 2019-9-30 2018-12-31
Current assets:
Cash and bank balances 2,544,212,671.60 1,817,654,598.01
Tradable financial assets
16
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Note receivable 33,503,980.32 63,870,980.39
Account receivable 759,614,729.17 631,236,593.94
Receivable financing 16,673,997.31
Advances to suppliers 3,026,025.81 4,760,182.00
Other receivable 1,866,735,563.06 1,541,980,883.50
Including: Interest receivable 16,497,156.40 7,550,877.07
Dividend receivable
Inventories 211,858,298.59 158,166,185.65
Contractual assets
Assets held for sale
Non-current assets maturing within
one year
Other current assets 39,482.38 39,482.38
Total current assets 5,435,664,748.24 4,217,708,905.87
Non-current assets:
Debt investment
Available-for-sale financial assets
Other debt investment
Held-to-maturity investments
Long-term receivables
Long-term equity investments 7,693,092,094.23 7,432,906,692.24
Investment in other equity
instrument
Other non-current financial assets 140,000,000.00 140,000,000.00
Investment properties 1,560,072.33 1,955,854.46
Fixed assets 15,474,034.96 21,362,422.03
Construction in progress
Productive biological assets
Oil and natural gas assets
Right-of-use assets 6,500,265.79
Intangible assets 2,783,945.44 2,452,222.51
17
Research and development costs
Goodwill
Long-term deferred expenses 6,527,719.68 7,481,809.53
Deferred income tax assets
Other non-current assets 7,000,000.00 7,000,000.00
Total non-current assets 7,872,938,132.43 7,613,159,000.77
Total assets 13,308,602,880.67 11,830,867,906.64
Current liabilities:
Short-term borrowings 280,000,000.00 539,000,000.00
Transactional financial liability
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 390,519,916.75 252,317,800.78
Account payable 630,198,511.72 442,049,241.22
Accounts received in advance
Contractual liability 1,694,562.86 4,182,083.40
Employee benefits payable 37,876,995.85 36,233,563.12
Taxes payable 9,336,735.58 13,426,601.90
Other payable 1,894,492,989.75 1,481,817,856.56
Incl: Interest payable 8,063,589.67 1,354,592.35
Dividends payable
Liability held for sale
Non-current liabilities due within
32,573,100.20
one year
Other current liabilities 292,740.68 226,427.99
Total current liabilities 3,276,985,553.39 2,769,253,574.97
Non-current liabilities:
Long-term borrowings 31,600,000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Lease liabilities 5,715,312.04
18
Long-term payables 800,000.00 800,000.00
Long-term employee benefits
102,000.00 118,000.00
payable
Accrued liabilities
Deferred income 1,388,958.78 1,687,899.50
Deferred tax liabilities 1,644,875.80 2,298,426.39
Other non-current liabilities
Total non-current liabilities 9,651,146.62 36,504,325.89
Total liabilities 3,286,636,700.01 2,805,757,900.86
Owners’ equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital surplus 4,468,787,524.26 4,426,362,777.26
Less: Inventory shares
Other comprehensive income
Special reserve
Surplus reserve 214,063,491.50 214,063,491.50
Retained earnings 4,910,988,181.90 3,956,556,754.02
Total shareholders’ equity 10,021,966,180.66 9,025,110,005.78
Total liabilities and shareholders’ equity 13,308,602,880.67 11,830,867,906.64
3. Consolidated Profit Statement (the period)
In RMB
Item Current Period Last Period
I. Total operating revenue 13,647,793,431.64 10,987,540,368.77
Including: Operating revenue 13,647,793,431.64 10,987,540,368.77
Interest revenue
Insurance gained
Commission charge and
commission revenue
II. Total operating costs 13,305,315,433.53 10,672,195,431.17
Including: Operating costs 12,253,508,326.76 9,749,853,630.20
19
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 36,513,174.49 30,175,966.21
Selling expense 763,231,928.31 682,736,449.56
Administrative expense 208,311,402.38 188,693,332.32
R&D expense
Finance costs 43,750,601.59 20,736,052.88
Incl: Interest cost 86,528,994.84 45,676,535.07
Interest income 42,778,570.08 26,253,068.71
Add: other income 12,116,753.12 1,815,373.95
Investment income (Loss is
86,069,936.49 78,983,284.46
listed with “-”)
Incl: Investment income from
86,019,936.49 78,933,284.46
associates
The termination of income
recognition for financial assets measured
by amortized cost(Loss is listed with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Impairment losses on financial
-3,211,918.65 -547,491.37
assets (Loss is listed with “-”)
Impairment losses (Loss is
-705,879.81 392,308.58
listed with “-”)
Gain on disposal of assets
613,909.71 76,479.50
(Loss is listed with “-”)
III. Operating profit (Loss is listed with 437,360,798.97 396,064,892.72
20
“-”)
Add: Non-operating income 3,202,332.16 1,553,611.12
Less: Non-operating expense 638,789.06 374,027.37
IV. Total profit (Loss is listed with “-”) 439,924,342.07 397,244,476.47
Less: Income taxes 80,632,027.90 76,038,019.79
V. Net profit (Net loss is listed with “-”) 359,292,314.17 321,206,456.68
(i) Classify by business continuity
1. Net Profit from continuing
359,292,314.17 321,206,456.68
operations (net loss listed with ‘-”)
2.termination of net profit (net loss
listed with ‘-”)
(ii) Attributable to
1. Owners of the parent 311,310,706.52 285,244,535.54
2. Non-controlling interests 47,981,607.65 35,961,921.14
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
21
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial assets
re-classify to other comprehensive
income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging reserve
8.Translation differences
arising on translation of foreign currency
financial statements
9.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 359,292,314.17 321,206,456.68
Total comprehensive income for the
yearattributable to shareholders of the 311,310,706.52 285,244,535.54
parent
Total comprehensive income for the
year attributable tonon-controlling 47,981,607.65 35,961,921.14
interests
VIII. Earnings per share:
(i) Basic earnings per share 0.735 0.666
(ii) Diluted earnings per share 0.735 0.666
As for the business merger under the same control in the Period, 0 Yuan net profit realized before merger by the
combined party, the net profit for combined party in last period was 0 Yuan.
Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
22
Item Current Period Last Period
I. Operating revenue 1,112,624,846.96 899,859,002.45
Less: Operating costs 1,064,701,021.03 856,296,603.88
Tax and surcharge 1,964,184.59 1,445,734.44
Selling expenses 17,984,619.36 16,953,141.79
Administrative expenses 24,299,300.83 16,785,749.55
R&D expenses
Financial costs -11,487,202.76 -10,270,272.65
Incl: Interest expense 15,442,321.41 10,951,050.33
Incl: Interest income 27,695,670.05 21,345,942.02
Add: other income 219,828.06 121,990.82
Investment income (Loss is
473,512,554.91 84,991,405.06
listed with “-”)
Incl: Investment income from
91,259,842.03 84,991,405.06
associates
The termination of
income recognition for financial assets
measured by amortized cost (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Impairment losses on
-161,522.25
financial assets (Loss is listed with “-”)
Impairment loss (Loss is
-234,019.78 152,059.06
listed with “-”)
Gain on disposal of assets
181,433.34 11,116.50
(Loss is listed with “-”)
II. Operating profits (Loss is listed with
488,681,198.19 103,924,616.88
“-”)
Add: Non-operating income 373.35 3.98
Less: Non-operating expense
III. Total Profit (Loss is listed with “-”) 488,681,571.54 103,924,620.86
Less: Income taxes 3,675,740.93 4,806,491.84
IV. Net profit (Net loss is listed with
485,005,830.61 99,118,129.02
“-”)
23
(i) Net Profit from continuing
485,005,830.61 99,118,129.02
operations (net loss listed with ‘-”)
(ii) termination of net profit (net
loss listed with ‘-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial
assets re-classify to other
comprehensive income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
24
7.Cash flow hedging
reserve
8.Translation differences
arising on translation of foreign
currency financial statements
9.Other
VI. Total comprehensive income 485,005,830.61 99,118,129.02
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Total operating revenue 38,875,940,809.07 31,766,707,068.44
Including: Operating revenue 38,875,940,809.07 31,766,707,068.44
Interest revenue
Insurance gained
Commission charge and
commission revenue
II. Total operating cost 37,747,619,061.94 30,779,410,046.43
Including: Operating costs 34,669,028,279.63 28,117,497,354.04
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 98,652,400.93 86,796,493.46
Salling expenses 2,246,564,429.04 1,956,325,205.63
Administrative expenses 585,528,096.51 540,513,396.10
R&D expense
25
Finance costs 147,845,855.83 78,277,597.20
Incl: Interest cost 256,058,467.21 129,032,902.25
Interest income 103,408,606.99 49,335,302.27
Add: other incomes 27,107,672.14 12,404,586.52
Investment income (Loss is
255,212,226.48 241,677,055.81
listed with “-”)
Incl: Investment income from
255,162,226.48 241,595,555.81
associates
The termination of income
recognition for financial assets measured
by amortized cost(Loss is listed with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Impairment losses on financial
-14,646,019.78 479,210.87
assets (Loss is listed with “-”)
Impairment losses (Loss is
-831,434.15 -116,540.68
listed with “-”)
Gain on disposal of assets
584,184.27 4,357,644.11
(Loss is listed with “-”)
III. Operating profit (Loss is listed with
1,395,748,376.09 1,246,098,978.64
“-”)
Add: Non-operating income 6,869,502.41 7,052,562.23
Less: Non-operating expense 2,357,054.62 2,171,320.17
IV. Total profit (Loss is listed with “-”) 1,400,260,823.88 1,250,980,220.70
Less: Income taxes 272,875,954.40 240,524,754.11
V. Net profit (Net loss is listed with “-”) 1,127,384,869.48 1,010,455,466.59
(i) Classify by business continuity
1. Net Profit from continuing
1,127,384,869.48 1,010,455,466.59
operations (net loss listed with ‘-”)
2.termination of net profit (net loss
listed with ‘-”)
(ii) Classify by ownership
1. Owners of the parent 962,144,066.92 926,971,570.47
2. Non-controlling interests 165,240,802.56 83,483,896.12
26
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial assets
re-classify to other comprehensive
income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging reserve
27
8.Translation differences
arising on translation of foreign currency
financial statements
9.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 1,127,384,869.48 1,010,455,466.59
Total comprehensive income for the
yearattributable to shareholders of the 962,144,066.92 926,971,570.47
parent
Total comprehensive income for the
year attributable tonon-controlling 165,240,802.56 83,483,896.12
interests
VIII. Earnings per share:
(i) Basic earnings per share 2.247 2.165
(ii) Diluted earnings per share 2.247 2.165
As for the business merger under the same control in the Period, 0 Yuan net profit realized before merger by the
combined party, the net profit for combined party in last period was 0 Yuan.
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Operating revenue 3,120,629,410.26 2,587,480,358.28
Less: Operating costs 2,985,973,415.79 2,471,014,077.79
Taxes and surcharge 4,483,432.58 3,462,103.37
Selling expenses 49,036,664.17 42,847,937.24
Administrative expenses 62,356,107.14 50,464,856.30
R&D expenses
Finance costs -39,885,446.76 -29,640,152.73
Incl: Interest expense 38,713,629.13 31,721,163.76
Incl: Interest income 80,175,392.47 62,271,142.76
Add: other income 552,592.19 1,421,335.96
Investment income (Loss is
1,081,800,975.38 619,832,149.52
listed with “-”)
Incl: Investment income from
272,540,375.14 258,317,695.20
associates
28
The termination of
income recognition for financial assets
measured by amortized cost (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Impairment losses on
-2,527,287.33 7,411.02
financial assets (Loss is listed with “-”)
Impairment loss (Loss is
-336,132.62 -478,894.27
listed with “-”)
Gain on disposal of assets
155,358.82 11,116.50
(Loss is listed with “-”)
II. Operating profit (Loss is listed with
1,138,310,743.78 670,124,655.04
“-”)
Add: Non-operating income 46,442.75 37.06
Less: Non-operating expenses 127,688.63
III. Total Profit (Loss is listed with “-”) 1,138,357,186.53 669,997,003.47
Less: Income taxes 12,674,965.45 11,099,365.68
IV. Net profit (Net loss is listed with
1,125,682,221.08 658,897,637.79
“-”)
(i) Net Profit from continuing
1,125,682,221.08 658,897,637.79
operations (net loss listed with ‘-”)
(ii) termination of net profit (net
loss listed with ‘-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
29
enterprise's credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial
assets re-classify to other
comprehensive income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging
reserve
8.Translation differences
arising on translation of foreign
currency financial statements
9.Other
VI. Total comprehensive income 1,125,682,221.08 658,897,637.79
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
30
Cash received from sales of good
39,464,106,244.18 33,576,126,717.79
or rendering of services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Net cash received by agents in sale
and purchase of securities
Tax refunds 3,508,074.72 1,714,760.21
Cash receipts related to other
497,412,494.23 503,409,429.80
operating activities
Sub-total of cash inflows from
39,965,026,813.13 34,081,250,907.80
operating activities
Cash paid for goods and services 35,594,093,946.44 30,058,268,141.08
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Net increase of capital lent
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
31
Cash paid to and on behalf of
1,592,033,194.68 1,392,220,211.12
employees
Cash paid for all types of taxes 941,789,797.45 818,864,295.31
Cash payments related to other
764,147,713.34 1,247,906,964.93
operating activities
Sub-total of cash outflows from
38,892,064,651.91 33,517,259,612.44
operating activities
Net cash flows from operating activities 1,072,962,161.22 563,991,295.36
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from returns on
78,242,963.78 130,963,345.37
investments
Net cash received from disposal of
fixed, intangible assets and other 4,967,658.92 5,751,674.16
long-term assets
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
4,514,498.90 101,261,607.73
investing activities
Sub-total of cash inflows from investing
87,725,121.60 237,976,627.26
activities
Cash paid for acquisition of fixed
assets, intangible assetsand other 162,770,914.81 150,353,192.93
long-term assets
Cash paid for acquisition of
84,539,317.61 90,000,000.00
investments
Net increase of mortgaged loans
Net cash paid from disposal of
5,328,000.00
subsidiaries and otherbusiness units
Cash payments related to other
1,603,306.28 79,921,476.82
investing activities
Sub-total of cash outflows from
254,241,538.70 320,274,669.75
investing activities activities
Net cash flows arising from investing
-166,516,417.10 -82,298,042.49
activities
III. Cash flows arising from financing
32
activities
Cash proceeds from investments
44,548,000.00 2,788,851,200.00
by others
Incl: Cash proceeds from
subsidiary investments by 44,548,000.00 2,788,851,200.00
non-controlling shareholders
Cash received from borrowings 16,700,000.00 49,670,200.30
Cash receipts related to other
1,967,629.61 108,949,307.54
financing activities
Subtotal of cash inflow from financing
63,215,629.61 2,947,470,707.84
activities
Cash repayments for debts 73,307,142.79 79,670,200.30
Cash payments for distribution of
450,504,620.79 276,628,059.98
dividends or profit andinterest expenses
Incl: Profit and dividends paid to
non-controllingshareholders of 28,493,123.11 56,858,945.30
subsidiaries
Cash payments related to other
604,680,365.03 60,658,096.82
financing activities s
Subtotal of cash outflow from financing
1,128,492,128.61 416,956,357.10
activities
Net cash flows from financing activities -1,065,276,499.00 2,530,514,350.74
IV.Effect of foreign exchange rate
changes on cash and cash equivalents
-175,994.42 -314,517.97
Influence on cash and cash equivalents
due to fluctuation in exchange rate
V. Net increasein cash and cash
-159,006,749.30 3,011,893,085.64
equivalents
Add: Cash and cash equivalents at
7,632,117,020.77 3,673,498,691.48
beginning of the year
VI. Cash and cash equivalents at end of
7,473,110,271.47 6,685,391,777.12
year
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
33
Cash received from sales of good
3,217,890,947.38 2,681,236,630.70
or rendering of services
Write-back of tax received
Cash receipts related to other
32,674,054.58 91,958,196.80
operating activities
Sub-total of cash inflows from
3,250,565,001.96 2,773,194,827.50
operating activities
Cash paid for goods and services 3,191,926,190.64 2,559,377,589.52
Cash paid to and on behalf of
73,601,798.69 61,913,310.95
employees
Cash paid for all types of taxes 43,156,828.71 29,801,808.96
Cash payments related to other
24,724,274.57 45,140,599.54
operating activities
Subtotal of cash outflow from operating
3,333,409,092.61 2,696,233,308.97
activities
Net cash flows arising from operating
-82,844,090.65 76,961,518.53
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from returns of
619,976,538.54 255,904,643.39
investments
Net cash received from disposal of
fixed assets, intangible assets and other 3,961,383.00 35,200.00
long-term assets
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
1,482,390,000.00 1,218,035,586.01
investing activities
Subtotal of cash inflow from investing
2,106,327,921.54 1,473,975,429.40
activities
Cash paid for acquisition of fixed
assets, intangible assets andother 6,777,035.03 8,607,026.77
long-term assets
Cash paid for investment 19,998,000.00 90,000,000.00
Net cash received from
subsidiaries and other units obtained
34
Cash payments related to other
1,812,850,181.28 1,267,321,606.82
investing activities
Subtotal of cash outflow from investing
1,839,625,216.31 1,365,928,633.59
activities
Net cash flows from investing activities
266,702,705.23 108,046,795.81
activities
III. Cash flows arising from financing
activities:
Cash received from absorbing
investment
Cash received from borrowings 10,000,000.00 10,000,000.00
Cash receipts related to other
18,437,509,464.22 12,559,913,378.52
financing activities
Subtotal of cash inflow from financing
18,447,509,464.22 12,569,913,378.52
activities
Cash repayments for debts 10,000,000.00 10,000,000.00
Cash payments for distribution of
191,576,803.94 153,116,428.79
dividends, profit or interestexpenses
Cash payments related to other
17,703,057,206.85 12,723,602,657.57
financing activities
Subtotal of cash outflow from financing
17,904,634,010.79 12,886,719,086.36
activities
Net cash flows from financing activities 542,875,453.43 -316,805,707.84
IV. .Effect of foreign exchange rate
-175,994.42 -314,517.97
changes on cash and cash equivalents
V. Net increase in cash and cash
726,558,073.59 -132,111,911.47
equivalents
Add: Cash and cash equivalents at
1,817,654,598.01 1,776,696,342.87
beginning of the year
VI. Cash and cash equivalents at end of
2,544,212,671.60 1,644,584,431.40
year
II. Financial statement adjustment
1. Relevant items of the financial statement at beginning of the year when implementing the new financial
instrument standards, new revenue standards or new leasing standards since 2019
√ Applicable □ Not applicable
Consolidated Balance Sheet
35
In RMB
Item 2018-12-31 2019-01-01 Adjustment
Current assets:
Monetary funds 8,089,781,304.56 8,089,781,304.56
Settlement provisions
Capital lent
Tradable financial assets
Financial assets
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
assets
Note receivable 1,357,311,929.63 789,536,654.23 -567,775,275.40
Account receivable 9,336,861,647.92 9,336,861,647.92
Receivable financing 567,775,275.40 567,775,275.40
Advances to suppliers 583,484,515.95 419,443,944.83 -164,040,571.12
Insurance receivable
Reinsurance receivables
Contract reserve of
reinsurance receivable
Other receivables 643,493,359.32 643,493,359.32
Including: Interest
8,223,327.64 8,223,327.64
receivable
Dividend
receivable
Buying back the sale of
financial assets
Inventories 4,389,335,942.19 4,389,335,942.19
Contractual assets
Assets held for sale
Non-current asset due
within one year
Other current assets 95,347,629.18 95,347,629.18
Total current assets 24,495,616,328.75 24,331,575,757.63 -164,040,571.12
Non-current assets:
36
Loans and payments on
behalf
Debt investment
Finance asset available
for sales
Other debt investment
Held-to-maturity
investment
Long-term account
receivable
Long-term equity
1,880,393,786.10 1,880,393,786.10
investment
Other equity instruments
13,685,760.00 13,685,760.00
investment
Other non-current
140,000,000.00 140,000,000.00
financial assets
Investment properties 144,894,495.97 144,894,495.97
Fixed assets 607,933,827.67 594,067,973.91 -13,865,853.76
Construction in progress 36,412,614.61 36,412,614.61
Productive biological
asset
Oil and gas asset
Right-of-use assets 1,782,725,159.78 1,782,725,159.78
Intangible assets 319,207,126.15 318,693,082.72 -514,043.43
Expense on Research
and Development
Goodwill 833,547,800.60 833,547,800.60
Long-term prepaid
311,328,706.46 311,328,706.46
expenses
Deferred tax assets 74,914,209.95 74,914,209.95
Other non-current asset 72,365,863.71 58,168,919.11 -14,196,944.60
Total non-current asset 4,434,684,191.22 6,188,832,509.21 1,754,148,317.99
Total assets 28,930,300,519.97 30,520,408,266.84 1,590,107,746.87
Current liabilities:
Short-term borrowings 2,597,652,702.43 2,597,652,702.43
Loan from central bank
37
Capital borrowed
Transactional financial
liability
Financial liability
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
liability
Note payable 3,416,755,681.80 3,416,755,681.80
Account payable 6,468,535,961.17 6,468,535,961.17
Accounts received in
advance
Contractual liability 255,590,612.37 255,590,612.37
Selling financial asset of
repurchase
Absorbing deposit and
interbank deposit
Security trading of
agency
Security sales of agency
Employee benefits
231,866,407.40 231,866,407.40
payable
Taxes payable 241,980,412.72 241,980,412.72
Other account payable 1,539,436,971.93 1,539,436,971.93
Incl: Interest payable 21,906,660.63 21,906,660.63
Dividend
6,389,320.96 6,389,320.96
payable
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities
5,861,324.37 495,132,751.96 489,271,427.59
due within one year
Other current liabilities 292,465.75 292,465.75
Total current liabilities 14,757,972,539.94 15,247,243,967.53 489,271,427.59
Non-current liabilities:
Insurance contract reserve
38
Long-term borrowings 31,600,000.00 31,600,000.00
Bonds payable
Including: Preferred
stock
Perpetual
capital securities
Lease liability 1,104,600,297.80 1,104,600,297.80
Long-term payable 4,563,978.52 800,000.00 -3,763,978.52
Long-term employee
2,050,000.00 2,050,000.00
benefits payable
Accrual liability
Deferred income 91,491,170.40 91,491,170.40
Deferred tax liabilities 67,605,161.88 67,605,161.88
Other non-current
69,241,176.18 69,241,176.18
liabilities
Total non-current liabilities 266,551,486.98 1,367,387,806.26 1,100,836,319.28
Total liabilities 15,024,524,026.92 16,614,631,773.79 1,590,107,746.87
Owner’s equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: Preferred
stock
Perpetual
capital securities
Capital surplus 4,320,984,981.51 4,320,984,981.51
Less: Inventory shares
Other comprehensive
income
Reasonable reserve
Surplus reserve 214,063,491.50 214,063,491.50
Provision of general risk
Retained earnings 6,655,257,147.27 6,655,257,147.27
Shareholders’ equity
attributable to shareholders 11,618,432,603.28 11,618,432,603.28
of the parent
Non-controlling 2,287,343,889.77 2,287,343,889.77
39
interests
Total shareholders’ equity 13,905,776,493.05 13,905,776,493.05
Total liabilities and
28,930,300,519.97 30,520,408,266.84 1,590,107,746.87
shareholders’ equity
Statement of adjustment
Balance Sheet of Parent Company
In RMB
Item 2018-12-31 2019-01-01 Adjustment
Current assets:
Cash and bank balances 1,817,654,598.01 1,817,654,598.01
Tradable financial assets
Financial assets
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
assets
Note receivable 63,870,980.39 34,154,774.75 -29,716,205.64
Account receivable 631,236,593.94 631,236,593.94
Receivable financing 29,716,205.64 29,716,205.64
Advances to suppliers 4,760,182.00 4,757,318.66 -2,863.34
Other receivable 1,541,980,883.50 1,541,980,883.50
Including: Interest
7,550,877.07 7,550,877.07
receivable
Dividend
receivable
Inventories 158,166,185.65 158,166,185.65
Contractual assets
Assets held for sale
Non-current assets
maturing within one year
Other current assets 39,482.38 39,482.38
Total current assets 4,217,708,905.87 4,217,706,042.53 -2,863.34
Non-current assets:
Debt investment
Available-for-sale
financial assets
40
Other debt investment
Held-to-maturity
investments
Long-term receivables
Long-term equity
7,432,906,692.24 7,432,906,692.24
investments
Investment in other
equity instrument
Other non-current
140,000,000.00 140,000,000.00
financial assets
Investment properties 1,955,854.46 1,955,854.46
Fixed assets 21,362,422.03 21,362,422.03
Construction in progress
Productive biological
assets
Oil and natural gas
assets
Right-of-use assets 6,827,171.38 6,827,171.38
Intangible assets 2,452,222.51 2,452,222.51
Research and
development costs
Goodwill
Long-term deferred
7,481,809.53 7,481,809.53
expenses
Deferred income tax
assets
Other non-current assets 7,000,000.00 7,000,000.00
Total non-current assets 7,613,159,000.77 7,619,986,172.15 6,827,171.38
Total assets 11,830,867,906.64 11,837,692,214.68 6,824,308.04
Current liabilities:
Short-term borrowings 539,000,000.00 539,000,000.00
Transactional financial
liability
Financial liability
measured by fair value and
with variation reckoned into
current gains/losses
41
Derivative financial
liability
Notes payable 252,317,800.78 252,317,800.78
Account payable 442,049,241.22 442,049,241.22
Accounts received in
advance
Contractual liability 4,182,083.40 4,182,083.40
Employee benefits
36,233,563.12 36,233,563.12
payable
Taxes payable 13,426,601.90 13,426,601.90
Other payable 1,481,817,856.56 1,481,817,856.56
Incl: Interest payable 1,354,592.35 1,354,592.35
Dividends
payable
Liability held for sale
Non-current liabilities
786,068.44 786,068.44
due within one year
Other current liabilities 226,427.99 226,427.99
Total current liabilities 2,769,253,574.97 2,770,039,643.41 786,068.44
Non-current liabilities:
Long-term borrowings 31,600,000.00 31,600,000.00
Bonds payable
Including: preferred
stock
Perpetual
capital securities
Lease liabilities 6,038,239.60 6,038,239.60
Long-term payables 800,000.00 800,000.00
Long-term employee
118,000.00 118,000.00
benefits payable
Accrued liabilities
Deferred income 1,687,899.50 1,687,899.50
Deferred tax liabilities 2,298,426.39 2,298,426.39
Other non-current
liabilities
Total non-current liabilities 36,504,325.89 42,542,565.49 6,038,239.60
42
Total liabilities 2,805,757,900.86 2,812,582,208.90 6,824,308.04
Owners’ equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: preferred
stock
Perpetual
capital securities
Capital surplus 4,426,362,777.26 4,426,362,777.26
Less: Inventory shares
Other comprehensive
income
Special reserve
Surplus reserve 214,063,491.50 214,063,491.50
Retained earnings 3,956,556,754.02 3,956,556,754.02
Total shareholders’ equity 9,025,110,005.78 9,025,110,005.78
Total liabilities and
11,830,867,906.64 11,837,692,214.68 6,824,308.04
shareholders’ equity
Statement of adjustment
2. Explanation on comparative data in the early stage of retroactive adjustment while implemented the new
financial instrument standards or new leasing standards since 2019
□ Applicable √ Not applicable
III. Audit report
Whether the 3rd quarterly report has been audited or not
□Yes √ No
The 3rd quarterly report of the Company has not been audited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
24 October 2019
43
